Researchers rely on a steady stream of volunteers to test and validate their products – yet clinical trial recruitment and retention are significant barriers to success.
With coronavirus now declared a pandemic by WHO, all eyes are on pharma and other healthcare companies to develop solutions – but the industry isn’t immune to workforce and economic threats
Rapidly-changing treatment landscapes in diseases like lung cancer pose challenges for medical education providers, who need to be more adaptable than ever.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
